Aastrom builds on stem cell success in heart failure
This article was originally published in Scrip
Aastrom Bioscience's stem cell treatment ixmyelocel-T has improved heart function in a Phase IIa study in patients with heart failure due to dilated cardiomyopathy.
You may also be interested in...
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.
Just over a year ago, AstraZeneca at last returned to growth and set about a reorganization that placed oncology at the heart of its plans for continued success. In Vivo talked to the executive vice-president of its Oncology Business Unit David Fredrickson about how the company hopes to become a major cancer player.